Three-year safety, efficacy, and renal outcomes of mitapivat treatment in sickle cell disease: results from the phase 2 open-label study

Key Points

• The central aim is to assess the safety, efficacy, and renal outcomes of mitapivat in patients with sickle cell disease over three years.
• Conducted a phase 2 open-label study
• Evaluated treatment effects over three years
• Monitored safety and renal outcomes
• Demonstrated positive safety profile for mitapivat
• Showed significant efficacy in managing sickle cell disease symptoms
• Indicated potential improvements in renal health outcomes

Abstract